Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Gu&#xe9;rin

Genitourinary Cancer

Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)

Eur Urol

Hayne D, Zhang AY, Thomas H, Krieger L, Ischia J, Anderson P, Srivastav RK, Green W, Grummet J, Bastick PA, Beardsley EK, Blatt A, Patel M, Chan L, Mitterdorfer A, Roberts M, Sengupta S, Winter M, Marx G, Bishop C, Cheung L, Hawks C, Martin A, McCombie SP, Redfern AD, Davis ID, Stockler MR

doi: 10.1016/j.eururo.2026.01.009

COMMENTED

Genitourinary Cancer

Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials

★ 1 Recommended and commented by Prof. Dr Richard Cathomas, Faculty Member

Eur Urol

Scilipoti P, Zaurito P, Longoni M, Colecchia M, Montorsi F, Salonia A, Mercinelli C, Maiorano B, Necchi A, Briganti A, Moschini M

doi: 10.1016/j.eururo.2025.12.022

COMMENTED

Genitourinary Cancer

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer

★ 1 Recommended and commented by Prof. Dr Richard Cathomas, Faculty Member

J Clin Oncol

Gore JL, Wolff EM, Nash MG, Comstock BA, Gilbert SM, Chang SS, Chisolm S, MacLean DB, Wright JL, Kates MR, Pohar KS, Guzzo TJ, Bivalacqua TJ, Nepple KG, Montgomery JS, Scarpato KR, Woldu SL, Master VA, Chen DYT, Mossanen M, Daneshmand S, O'Neil BB, Tyson MD, Westerman ME, Kamat AM, Mansour AM, Chamie K, Riggs SB, Kukreja JB, Modi PK, Garg T, Peyton CC, Nix JW, Dickstein R, Gadzinski AJ, Sankin A, Shore ND, Lane BR, Bassett JC, Patel S, Morris DS, Macleod LC, Lee EK, Ritch CR, Follmer KM, Lee JR, Kim SM, Kessler LG, Smith AB, CISTO Collaborative group

doi: 10.1200/JCO-25-01324

Genitourinary Cancer

Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial

Eur Urol

Kitamura H, Tsukamoto T, Kakehi Y, Mizusawa J, Shibata T, Sasaki K, Tanikawa T, Hashine K, Fujimoto K, Masumori N, Kobayashi T, Habuchi T, Kimura T, Sugimoto M, Takahashi A, Adachi H, Matsui Y, Hatakeyama S, Ito A, Eto M, Nishiyama H, Urologic Oncology Study Group of the Japan Clinical Oncology Group

doi: 10.1016/j.eururo.2026.01.008

Genitourinary Cancer

Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer

BJU Int

Scilipoti P, Zaurito P, Longoni M, Tremolada G, Occhi A, Dutto D, Katzendorn O, Krajewski W, Laukhtina E, Elena JLR, Aranda J, Contieri R, Hurle R, Subiela JD, Lucena PE, Fernández A, Marcq G, Szostek A, Pichler R, Álvarez-Maestro M, Bazán AA, Klatte T, du Biest AM, Ferrando V, Buisan O, López AV, Soria F, Pradere B, D Andrea D, Shariat SF, Colecchia M, Montorsi F, Briganti A, Gontero P, Xylinas E, Moschini M, European Association of Urology – Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group and the EuroGemDoce Study Group Collaborators

doi: 10.1111/bju.70182

Genitourinary Cancer

UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial

J Urol

Prasad SM, Shishkov D, Mihaylov NV, Genov P, Terzi V, Kates M, Huang WC, Louie MJ, Burger B, Meads A, Schoenberg M

doi: 10.1097/JU.0000000000005041

Genitourinary Cancer

Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer

BJU Int

Abou Chakra M, McElree IM, Mott SL, O'Donnell MA

doi: 10.1111/bju.70149

Genitourinary Cancer

Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer

BJU Int

McElree IM, Steinberg RL, Hougen HY, Mott SL, Packiam VT, O'Donnell MA

doi: 10.1111/bju.70044

Genitourinary Cancer

External validation of the Uromonitor®-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management

BJU Int

Rubio-Briones J, Guerrero Ramos F, Mercadé Sánchez A, Bezana Abadía I, Rodríguez RM, Alcaraz A, Miqueleiz Legaz M, Lozano F, Arrabal Martín M, Luis Cardo A, Gonzalo Rodríguez V, Caño Velasco J, Serrano Liesa M, Ferreiro Pareja C, Espílez Ortiz R, de González-Valcárcel de Torres I, Sánchez Zalabardo D, Esquinas C, Mengual L, Borque-Fernando A, Esteban Escaño LM, Palou Redorta J, Witjes F, Martínez Piñeiro L

doi: 10.1111/bju.70010

Oncology · Hematology

Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guérin

Related content

Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)

Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer

Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial

Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer

UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial

Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer

Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer

External validation of the Uromonitor®-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management